Sign In
Buy PBYI
$6.81
-0.170 (-2.44%)
At Close: Jun 03, 2026
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
05:00pm, Wednesday, 03'rd Jun 2026
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on June 1, 2026, the Compensation Committee of Puma's Board of Directors approved the
Puma Biotechnology Q1 Earnings Call Highlights
04:03pm, Friday, 08'th May 2026
Puma Biotechnology NASDAQ: PBYI reported first-quarter 2026 total revenue of $44.8 million, driven primarily by NERLYNX product revenue net of $42.0 million and royalty revenue of $2.8 million, accord
PBYI Q1 Earnings & Sales Beat Estimates, 2026 Guidance Raised
01:05pm, Friday, 08'th May 2026
Puma Biotechnology beats Q1 earnings and revenue estimates while raising its 2026 outlook.
Puma Biotechnology, Inc. (PBYI) Q1 2026 Earnings Call Transcript
09:36am, Friday, 08'th May 2026
Puma Biotechnology, Inc. (PBYI) Q1 2026 Earnings Call Transcript
Puma Biotech (PBYI) Reports Q1 Loss, Tops Revenue Estimates
08:05pm, Thursday, 07'th May 2026
Puma Biotech (PBYI) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to earnings of $0.1 per share a year ago.
Puma Biotechnology Reports First Quarter 2026 Financial Results
04:05pm, Thursday, 07'th May 2026
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology hosted a conference call and provided a corporate update on May 7, 2026, following release of its 1Q-2026 financial results.
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
05:15pm, Wednesday, 06'th May 2026
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology reported inducement awards granted to six new hires in April 2026, as required under Nasdaq Listing Rule 5635(c)(4) .
Gun Makers Reach Cooperation Pact After Months of Tense Proxy Battle
09:37am, Monday, 04'th May 2026
Under the terms of their new agreement, Beretta may increase its investment in Sturm, Ruger to up to 25% of outstanding shares, including a tender offer at a minimum of $44.80 a share.
Puma Biotechnology to Host Conference Call to Discuss First Quarter 2026 Financial Results
04:15pm, Thursday, 23'rd Apr 2026
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology will host a conference call on May 7 at 1:30 p.m. PT, following release of its first quarter 2026 financial results.
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
05:15pm, Thursday, 02'nd Apr 2026
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on April 1, 2026, the Compensation Committee of Puma's Board of Directors approved th
Puma Biotechnology (NASDAQ:PBYI) Stock Crosses Above 200 Day Moving Average – Should You Sell?
02:30am, Tuesday, 31'st Mar 2026
Puma Biotechnology, Inc. (NASDAQ: PBYI - Get Free Report) shares passed above its 200-day moving average during trading on Monday. The stock has a 200-day moving average of $5.76 and traded as high as
Puma Biotechnology Stock Declines More Than 9% in a Month: Here's Why
12:30pm, Wednesday, 18'th Mar 2026
PBYI stock drops over 9% as weak 2026 revenue guidance and heavy reliance on Nerlynx raise concerns despite modest sales growth.
IRWD vs. PBYI: Which Small-Cap Biotech Stock Is a Better Buy?
01:35pm, Thursday, 12'th Mar 2026
Ironwood and Puma Biotechnology are developing GI and cancer therapies, respectively, with sales of their sole drugs expected to support 2026 revenues.
PBYI Q4 Earnings & Sales Beat Estimates, Stock Down on Weak 2026 View
01:35pm, Friday, 27'th Feb 2026
Puma Biotechnology Q4 earnings top estimates with 28% revenue jump, but weak 2026 outlook sparks 14% after-hours plunge.
Puma Biotechnology, Inc. (PBYI) Q4 2025 Earnings Call Transcript
09:37pm, Thursday, 26'th Feb 2026
Puma Biotechnology, Inc. (PBYI) Q4 2025 Earnings Call Transcript
